TITLE

CORRECTIONS

PUB. DATE
June 2008
SOURCE
Gut;Jun2008, Vol. 57 Issue 6, p872
SOURCE TYPE
Academic Journal
DOC. TYPE
Correction notice
ABSTRACT
The article presents corrections to the articles which include "Current treatment of hepatitis B," by G. Dusheiko, and N. Antonakopoulos, and "Intussusception in a 51-year-old male," by R. Persiani, A. Biondi, L. Larocca, and colleagues.
ACCESSION #
32531226

 

Related Articles

  • Entecavir outlasts the alternatives for affordable hep B therapy.  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p1 

    The article discusses research on the cost-effectiveness of the longer-term treatment, short-term treatment and entecavir for patients with HBeAg-negative chronic hepatitis B. It references a study by D. L. Veenstra and colleagues published in the June 15, 2008 issue of "Alimentary Pharmacology...

  • Chronic viral hepatitis B and C: What you need to know in 1995.  // Modern Medicine;Apr95, Vol. 63 Issue 4, p29 

    Presents Willis C. Maddrey's tips for the treatment of chronic viral hepatitis B and C. Chronicity of hepatitis C; Use of interferon alfa-2b in treating hepatitis; Use of ursodiol for treatment failures; Antigens associated with hepatitis.

  • Tenofovir does well in chronic hepatitis B treatment comparison.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p9 

    The article discusses research on the cost effectiveness of tenofovir in treating chronic hepatitis B in Taiwan. It references the study "Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B," by M. Buti and colleagues, published in the...

  • Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Whittle, Hilton; Jaffar, Shabbar; Wansbrough, Michael; Mendy, Maimuna; Dumpis,, Uga; Collinson, Andrew; Hall, Andrew // BMJ: British Medical Journal (International Edition);9/14/2002, Vol. 325 Issue 7364, p569 

    Abstract Objective: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design: Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting:...

  • Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. Hass, Holger G.; Bock, Thomas; Nehls, Oliver; Kaiser, Stephan // Journal of Gastroenterology;2009, Vol. 44 Issue 8, p871 

    The aim of the study was to estimate the effect of viral factors (HBV genotype, viral load and kinetics) to treatment response in chronic hepatitis B (CHB) and first-line therapy with adefovir dipivoxil (ADV). Sixty-six patients (60% males, 65% HBeAg negative) were treated with 10 mg ADV QD....

  • HBV DRUG RESISTANCE: ITS RELEVANCE IN CLINICAL PRACTICE. Hazam, Rajib Kishore; Kar, Premashis // Hepatitis B Annual;2007, Vol. 4, p24 

    Drug resistance can be considered as a natural response to the selective pressure of the drug. An increase in HBV DNA can be a good indicator of the presence of a resistant HBV mutant population. The nucleoside analogues Lamivudine, Adefovir, Entecavir etc. are oral drugs used for Hepatitis B...

  • Causes of Death and Characteristics of Decedents With Viral Hepatitis, United States, 2010. Ly, Kathleen N.; Xing, Jian; Klevens, R. Monina; Jiles, Ruth B.; Holmberg, Scott D. // Clinical Infectious Diseases;Jan2014, Vol. 58 Issue 1, p40 

    In 2010, three-fourths of 18 473 viral hepatitis–related deaths occurred among persons aged 45–64 years. Decedents who had a hepatitis B- or C-related death died 22–23 years younger than decedents who did not have a hepatitis B- or C-related death.Background. Previous...

  • Therapeutic options for chronic hepatitis B in 2013. Asselah, Tarik; Marcellin, Patrick // Hot Topics in Viral Hepatitis;2013, Vol. 9 Issue 28, p8 

    In recent years, many improvements have been made in prevention and treatment of hepatitis B virus (HBV) infection--one of the major causes of chronic hepatic diseases: cirrhosis and hepatocellular carcinoma (HCC). The aim of this therapy is preventing the progression of the disease through...

  • EVALUATION OF HEPATOPROTECTIVE ACTIVITY OF ALOE VERA IN ACUTE VIRAL HEPATITIS. Bhatt, Shaily; Virani, Shalini; Sharma, Monica; Kumar, Harshvardhan; Saxena, K. K. // International Journal of Pharmaceutical Sciences & Research;2014, Vol. 5 Issue 6, p2469 

    Background & objectives: Liver diseases are one of the major causes of disease burden all over world including our country so it is the need of hour to search for alternative drugs for the treatment of liver diseases. Aloe Vera is one of the most popular plants in the world, and is has been used...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics